Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation

BJU International

Volumn 99, Issue 5, 2007, Pages 1066-1071

  Acher, Peter L ^a   Popert, Rick ^a,b   Morris, Stephen L ^a   Potters, Louis ^c   Austin Smith, Susan L ^a   Johnson, Ursula H ^a   Nichol, Janette E ^a   Beaney, Ronald P ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b CROMWELL HOSPITAL   (United Kingdom)

^c SOUTH NASSAU COMMUNITIES HOSPITAL   (United States)

Author keywords

Brachytherapy; Prostate cancer; Prostate neoplasm; Size

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER NECK STENOSIS; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DOSIMETRY; FISHER EXACT TEST; HUMAN; IMPLANT; INCISION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; ORGAN SIZE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; STATISTICAL SIGNIFICANCE; SYMPTOM; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TREATMENT PLANNING; URINE RETENTION;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME; URINARY BLADDER NECK OBSTRUCTION;

EID: 34247129059     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06727.x     Document Type: Article

References (34)

1. Potters L, Morgenstern C, Calugaru E et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005; 173: 1562-6
2. Ragde H, Grado GL, Nadir BS. Brachytherapy for clinically localized prostate cancer: thirteen-year diseasefree survival of 769 consecutive prostate cancer patients treated with permanent implants alone. Arch Esp Urol 2001; 54: 739-47
3. Kupelian PA, Potters L, Khuntia D et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 25-33
4. Wang H, Wallner K, Sutlief S, Blasko J, Russell K, Ellis W. Transperineal brachytherapy in patients with large prostate glands. Int J Cancer 2000; 90: 199-205
5. Stone NN, Stock RG. Prostate brachytherapy in patients with prostate volumes >/= 50 cm(3): dosimetic analysis of implant quality. Int J Radiat Oncol Biol Phys 2000; 46: 1199-204
6. Niehaus A, Merrick GS, Butler WM et al. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006; 64: 136-43
7. Ash D, Flynn A, Battermann J, de Reijke T, Lavagnini P, Blank L. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000; 57: 315-21
8. Langley S, Laing R, Henderson A et al. European collaborative group on prostate brachytherapy: preliminary report in 1175 patients. Eur Urol 2004; 46: 565-70
9. Prestidge BR, Prete JJ, Buchholz TA et al. A survey of current clinical practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys 1998; 40: 461-5
10. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999; 44: 789-99
11. Crook J, McLean M, Catton C, Yeung I, Tsihlias J, Pintilie M. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 2002; 52: 453-60
12. Potters L, Calguaru E, Thornton KB, Jackson T, Huang D. Toward a dynamic real-time intraoperative permanent prostate brachytherapy methodology. Brachytherapy 2003; 2: 172-80
13. Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group, 43. American Association of Physicists in Medicine. Med Phys 1995; 22: 209-34
14. Meigooni AS, Dini SA, Sowards K, Hayes JL, Al Otoom A. Experimental determination of the TG-43 dosimetric characteristics of EchoSeed model 6733 I25I brachytherapy source. Med Phys 2002; 29: 939-42
15. Moran BJ, Stutz MA, Gurel MH. Prostate brachytherapy can be performed in selected patients after transurethral resection of the prostate. Int J Radiat Oncol Biol Phys 2004; 59: 392-6
16. Potters L, Huang D, Calugaru E, Fearn P, Lee L, Kattan MW. Importance of implant dosimetry for patients undergoing prostate brachytherapy. Urology 2003; 62: 1073-7
17. Stock RG, Stone NN, Dahlal M, Lo YC. What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, post-treatment prostate biopsies, and long-term urinary symptoms. Brachytherapy 2002; 1: 83-9
18. Potters L, Cao Y, Calugaru E, Torre T, Fearn P, Wang XH. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001; 50: 605-14
19. Potters L, Calugaru E, Jassal A, Presser J. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy? Int J Radiat Oncol Biol Phys 2006; 65: 1014-9
20. D'Amico AV, Davis A, Vargas SO, Renshaw AA, Jiroutek M, Richie JP. Defining the implant treatment volume for patients with low risk prostate cancer: does the anterior base need to be treated? Int J Radiat Oncol Biol Phys 1999; 43: 587-90
21. Ash D, Al Qaisieh B, Bottomley DM, Carey B. Assessment of implant quality for prostate brachytherapy - is D(90) the best quality index? Int J Radiat Oncol Biol Phys 2002; 54: 1287-8
22. Sherertz T, Wallner K, Wang H, Sutlief S, Russell K. Long-term urinary function after transperineal brachytherapy for patients with large prostate glands. Int J Radiat Oncol Biol Phys 2001; 51: 1241-5
23. Bellon J, Wallner K, Ellis W, Russell K, Cavanagh W, Blasko J. Use of pelvic CT scanning to evaluate pubic arch interference of transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999; 43: 579-81
24. McNeely LK, Stone NN, Presser J, Chircus JH, Stock RG. Influence of prostate volume on dosimetry results in real-time 125I seed implantation. Int J Radiat Oncol Biol Phys 2004; 58: 292-9
25. Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998; 160: 1379-82
26. Henderson A, Ismail AK, Cunningham M et al. Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK. A prospective study. Clin Oncol (R Coll Radiol) 2004; 16: 95-104
27. Keyes M, Schellenberg D, Moravan V et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve? Int J Radiat Oncol Biol Phys 2006; 64: 825-34
28. Martens C, Pond G, Webster D, McLean M, Gillan C, Crook J. Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. Brachytherapy 2006; 5: 9-13
29. Ash D, Al Qaisieh B, Bottomley D, Carey B, Joseph J. The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer. Radiother Oncol 2005; 75: 303-6
30. Potters L, Torre T, Ashley R, Leibel S. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 2000; 18: 1187-92
31. Bice WS Jr, Prestidge BR, Grimm PD et al. Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998; 41: 921-7
32. Desai J, Stock RG, Stone NN, Iannuzzi C, De Wyngaert JK. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Investig 1998; 6: 135-41
33. Blasko JC, Ragde H, Grimm PD. Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol Suppl 1991; 137: 113-8
34. Cesaretti JA, Stone NN, Stock RG. Does prior transurethral resection of prostate compromise brachytherapy quality: a dosimetric analysis. Int J Radiat Oncol Biol Phys 2004; 60: 648-53